Last reviewed · How we verify
Stem Cell Educator Therapy in Type 2 Diabetes
Type 2 diabetes is the most common form of diabetes. The prevalence of diabetes has been markedly increased in recent years. More and more children and young adults develop this devastating disease. Despite of multiple factors (e.g., food, environmental, and genetic factors) contributing to the developing of diabetes, increasing evidence demonstrated that chronic inflammation and/or atuoimmunity are common issues and play key roles in the pathogenesis of type 2 diabetes, leading to the insulin resistance and the shortage of insulin-producing islet beta cells. Thus, anti-inflammation is becoming a novel approach for the treatment of type 2 diabetes. Evidence that multipotent stem cells derived from human cord blood (CB-SCs) can control inflammation and autoimmune responses by altering regulatory T cells (Tregs) and human islet beta cell-specific T cell clone in type 1 diabetes offers promise for a new approach to treat type 2 diabetes. Here, the investigators develop a novel Stem Cell Educator therapy by using CB-SC and explore the therapeutic effectiveness of Stem Cell Educator therapy in T2D patients.
Details
| Lead sponsor | University of Illinois at Chicago |
|---|---|
| Phase | Phase 1/Phase 2 |
| Status | COMPLETED |
| Enrolment | 25 |
| Start date | 2011-07 |
| Completion | 2012-02 |
Conditions
- Type 2 Diabetes
Interventions
- Stem Cell Educator
Primary outcomes
- Inflammation control — 30 days post treatment
Before treatment, test inflammation-related markers as baseline; After treatment for 30 days, repeat testing inflammation-related markers.
Countries
China